Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David F McDermott

Showing results (41-50 of 227) with videos related to

Pageof 23
Sort By:
Journal of Oncology Practice|June 1, 2017
Improving End-of-Life Care: Palliative Care Embedded in an Oncology Clinic Specializing in Targeted and Immune-Based TherapiesDavid J Einstein, Susan DeSanto-Madeya, Matthew Gregas, et al.
JAMA Oncology|July 17, 2015
Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical TrialsJames Larkin, Christopher D Lao, Walter J Urba, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association|July 11, 2009
Refining indications for contemporary surgical treatment of renal cell carcinoma metastatic to the pancreasAram N Demirjian, Charles M Vollmer, David F McDermott, et al.
Immunotherapy|March 12, 2019
Comparative efficacy of combination immunotherapy and targeted therapy in the treatment of BRAF-mutant advanced melanoma: a matching-adjusted indirect comparisonMichael B Atkins, Ahmad Tarhini, Michael Rael, et al.
Immunotherapy|January 30, 2020
Clinical and economic outcomes of treatment sequences for intermediate- to poor-risk advanced renal cell carcinomaApoorva Ambavane, Shuo Yang, Michael B Atkins, et al.
Journal of Personalized Medicine|January 7, 2015
The Use of Registries to Improve Cancer Treatment: A National Database for Patients Treated with Interleukin-2 (IL-2)Howard L Kaufman, Michael K Wong, Gregory A Daniels, et al.
Cancer Medicine|October 25, 2013
FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancerJames L Chen, Daniel E Appelbaum, Masha Kocherginsky, et al.
Journal for Immunotherapy of Cancer|July 18, 2014
Implementation of an Interleukin-2 National Registry: an opportunity to improve cancer outcomesMichael K Wong, Howard L Kaufman, Gregory A Daniels, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|September 8, 2018
Quality-adjusted survival of nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone among treatment-naive patients with advanced melanoma: a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysisDavid F McDermott, Ruchit Shah, Komal Gupte-Singh, et al.
Cancer|March 28, 2006
Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacyKen Wyman, Michael B Atkins, Victor Prieto, et al.
Pageof 23

Showing results (41-50 of 227) with videos related to

Sort By:
Pageof 23
Journal of Oncology Practice|June 1, 2017
Improving End-of-Life Care: Palliative Care Embedded in an Oncology Clinic Specializing in Targeted and Immune-Based TherapiesDavid J Einstein, Susan DeSanto-Madeya, Matthew Gregas, et al.
JAMA Oncology|July 17, 2015
Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical TrialsJames Larkin, Christopher D Lao, Walter J Urba, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association|July 11, 2009
Refining indications for contemporary surgical treatment of renal cell carcinoma metastatic to the pancreasAram N Demirjian, Charles M Vollmer, David F McDermott, et al.
Immunotherapy|March 12, 2019
Comparative efficacy of combination immunotherapy and targeted therapy in the treatment of BRAF-mutant advanced melanoma: a matching-adjusted indirect comparisonMichael B Atkins, Ahmad Tarhini, Michael Rael, et al.
Immunotherapy|January 30, 2020
Clinical and economic outcomes of treatment sequences for intermediate- to poor-risk advanced renal cell carcinomaApoorva Ambavane, Shuo Yang, Michael B Atkins, et al.
Journal of Personalized Medicine|January 7, 2015
The Use of Registries to Improve Cancer Treatment: A National Database for Patients Treated with Interleukin-2 (IL-2)Howard L Kaufman, Michael K Wong, Gregory A Daniels, et al.
Cancer Medicine|October 25, 2013
FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancerJames L Chen, Daniel E Appelbaum, Masha Kocherginsky, et al.
Journal for Immunotherapy of Cancer|July 18, 2014
Implementation of an Interleukin-2 National Registry: an opportunity to improve cancer outcomesMichael K Wong, Howard L Kaufman, Gregory A Daniels, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|September 8, 2018
Quality-adjusted survival of nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone among treatment-naive patients with advanced melanoma: a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysisDavid F McDermott, Ruchit Shah, Komal Gupte-Singh, et al.
Cancer|March 28, 2006
Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacyKen Wyman, Michael B Atkins, Victor Prieto, et al.
Pageof 23